Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Biodexa’s Licensor Emtora To Announce Phase 2 Clinical Trial Results Of eRapa In Familial Adenomatous Polyposis To Be Presented At Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingBiodexa Pharmaceuticals
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations.
RenovaroCube, Wholly Owned Subsidiary Of Renovaro, Unveils Flamingo, A Multi-Cancer Detection Model Contributing To Its Mission To Transform Early Cancer Diagnostics
RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish trend with potential for further downside.
Eli Lilly’s Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
"Eli Lilly & Co's Q1 2024: Revenue hits $8.8 billion, up 26% Y/Y, driven by volume & higher prices. Strong demand for key drugs like Mounjaro & Verzenio. EPS beats at $2.58. FY24 guidance raised to $42.4 billion-$43.6 billion, citing robust performance.
ARS Pharmaceuticals Submits Response For neffy Marketing Authorization Application To EMA’s CHMP And Enters License Agreement With CSL Seqirus For Commercialization Of neffy In Australia And New Zealand
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of
Wave Life Sciences Announces Approval Of First Clinical Trial Application For RestorAATion-2 Trial Of WVE-006 In Individuals With Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the approval of its first clinical trial
NeuroBo To Present Latest Pre-Clinical Data On Cardiometabolic Assets, DA-1241 And DA-1726, Targeting MASH And Obesity, At Scientific Conferences In June
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the acceptance of poster presentations for its
Vaxart Announces Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers; Long-Term Goal Is To Provide Protection To Infants Through Passive Antibody Transfer
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transferSOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE)